company background image
PTN logo

Palatin Technologies DB:PTN Stock Report

Last Price

€0.95

Market Cap

€18.2m

7D

9.2%

1Y

-59.1%

Updated

23 Dec, 2024

Data

Company Financials +

Palatin Technologies, Inc.

DB:PTN Stock Report

Market Cap: €18.2m

PTN Stock Overview

A biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. More details

PTN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Palatin Technologies, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Palatin Technologies
Historical stock prices
Current Share PriceUS$0.95
52 Week HighUS$5.05
52 Week LowUS$0.63
Beta0.91
1 Month Change8.45%
3 Month Change8.82%
1 Year Change-59.05%
3 Year Change-91.72%
5 Year Change-94.65%
Change since IPO-99.78%

Recent News & Updates

Recent updates

Shareholder Returns

PTNDE BiotechsDE Market
7D9.2%-3.5%-2.0%
1Y-59.1%-14.7%6.9%

Return vs Industry: PTN underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: PTN underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is PTN's price volatile compared to industry and market?
PTN volatility
PTN Average Weekly Movement19.5%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PTN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PTN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
198630Carl Spanapalatin.com

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.

Palatin Technologies, Inc. Fundamentals Summary

How do Palatin Technologies's earnings and revenue compare to its market cap?
PTN fundamental statistics
Market cap€18.18m
Earnings (TTM)-€31.10m
Revenue (TTM)€2.29m

7.9x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTN income statement (TTM)
RevenueUS$2.38m
Cost of RevenueUS$23.23m
Gross Profit-US$20.84m
Other ExpensesUS$11.51m
Earnings-US$32.35m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.66
Gross Margin-874.25%
Net Profit Margin-1,357.06%
Debt/Equity Ratio0%

How did PTN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:13
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Palatin Technologies, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Joseph PantginisH.C. Wainwright & Co.
Kumaraguru RajaNOBLE Capital Markets, Inc.